Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial

The Lancet Oncology

Volumn 16, Issue 1, 2015, Pages 47-56

  Bartelink, Harry ^a   Maingon, Philippe ^b   Poortmans, Philip ^c,g   Weltens, Caroline ^d   Fourquet, Alain ^e   Jager, Jos ^f   Schinagl, Dominic ^g   Oei, Bing ^c   Rodenhuis, Carla ^h   Horiot, Jean Claude ⁱ   Struikmans, Henk ^h   Van Limbergen, Erik ^d   Kirova, Youlia ^e   Elkhuizen, Paula ^a   Bongartz, Rudolf ^j   Miralbell, Raymond ^k   Morgan, David ^l   Dubois, Jean Bernard ^m   Remouchamps, Vincent ⁿ   Mirimanoff, René Olivier ^o   Collette, Sandra ^p   Collette, Laurence ^p   more..

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b CENTRE GEORGES FRANÇOIS LECLERC   (France)

^c Institute Verbeeten   (Netherlands)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e INSTITUT CURIE   (France)

^f MAASTRO CLINIC   (Netherlands)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁱ CLINIQUE DE GENOLIER   (Switzerland)

^j UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^k GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^l NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^m CENTRE VAL D AURELLE   (France)

ⁿ Clinique & Maternite Sainte Elisabeth Namer   (Belgium)

^o Laboratory of Clinique de La Source   (Switzerland)

^p EORTC DATA CENTER   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADULT; AGE; ARTICLE; BREAST CANCER; BREAST FIBROSIS; CANCER CONTROL; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; INTRADUCTAL CARCINOMA; MAMMOGRAPHY; MIDDLE AGED; MULTICENTER STUDY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PHASE 3 CLINICAL TRIAL; PREMENOPAUSE; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT FAILURE; TUMOR RECURRENCE; TUMOR VOLUME; ADJUVANT THERAPY; ADVERSE EFFECTS; AUSTRALIA; BREAST NEOPLASMS; CLINICAL TRIAL; EUROPE; FIBROSIS; INTENTION TO TREAT ANALYSIS; ISRAEL; KAPLAN MEIER METHOD; MASTECTOMY; MORTALITY; PATHOLOGY; PATIENT SELECTION; PROPORTIONAL HAZARDS MODEL; REOPERATION; SEGMENTAL MASTECTOMY; TIME; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AUSTRALIA; BREAST NEOPLASMS; EUROPE; FEMALE; FIBROSIS; HUMANS; INTENTION TO TREAT ANALYSIS; ISRAEL; KAPLAN-MEIER ESTIMATE; MASTECTOMY; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; REOPERATION; SALVAGE THERAPY; TIME FACTORS; TREATMENT OUTCOME;

EID: 84924967706     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)71156-8     Document Type: Article

References (34)

1. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet 2011, 378:1707-1716. Early Breast Cancer Trialists' Collaborative Group.
2. Bartelink H, Horiot JC, Poortmans P, et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 2001, 345:1378-1387.
3. Bartelink H, Horiot JC, Poortmans PM, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 2007, 25:3259-3265.
4. Romestaing P, Lehingue Y, Carrie C, et al. Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. J Clin Oncol 1997, 15:963-968.
5. Pocock SJ, Simon R Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975, 31:103-115.
6. Poortmans PM, Collette L, Horiot JC, et al. Radiation Oncology and Breast Cancer Groups. Impact of the boost dose of 10 Gy versus 26 Gy in patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10-year results of the randomised EORTC boost trial. Radiother Oncol 2009, 90:80-85.
7. International Commission of Radiation Units and Measurements: Dose specification for reporting external beam therapy with photons and electrons: report 50 1992, ICRU, Bethesda.
8. Kalbfleisch JD, Prentice RL The statistical analysis of failure time data 2002, John Wiley, Hoboken. 2nd edn.
9. Fine JP, Gray RJ A proportional hazards model for the subdistribution of competing risk. J Am Stat Assoc 1999, 94:496-509.
10. Fisher B, Bauer M, Margolese R, et al. Five year results of a randomized trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 1985, 312:665-673.
11. Veronesi U, Delvecchio H, Greco MA, et al. Results of quadrantectomy, axillary dissection and radiotherapy (QUART) in T1N0 patients. Conservative management of breast cancer. New surgical and radiotherapeutic techniques 1983, 91-101. JB Lippincott Company, Philadelphia. J.R. Harris, S. Hellman, W. Silen (Eds.).
12. Sarrazin D, Le M, Fontaine MF, Arriagada R Conservative treatment versus mastectomy in or small T2 breast cancer - a randomized clinical trial. Conservative management of breast cancer. New surgical and radiotherapeutic techniques 1983, 101-111. JB Lippincott Company, Philadelphia. J.R. Harris, S. Hellman, W. Silen (Eds.).
13. Litière S, Werutsky G, Fentiman IS, et al. Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol 2012, 13:412-419.
14. Bartelink H, Bourgier C, Elkhuizen P Has partial breast irradiation by IORT or brachytherapy been prematurely introduced into the clinic?. Radiother Oncol 2012, 104:139-142.
15. Elkhuizen P, Van de Vijver MJ, Hermans JO, et al. Local recurrence after breast-conserving therapy for invasive breast cancer: high incidence in young patients and association with poor survival. Int J Radiat Oncol Biol Phys 1998, 40:859-867.
16. Vrieling C, Fourquet A, Hoogenraad WJ, et al. Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients?. Eur J Cancer 2003, 39:932-944. on behalf of the EORTC Radiotherapy, Breast Cancer Groups.
17. Bollet MA, Sigal-Zafrani B, Mazeau V, et al. Age remains the first prognostic factor for loco-regional breast cancer recurrence in young women treated with breast conserving surgery first. Radiother Oncol 2007, 82:272-280.
18. Polgar C, Fodor J, Orosz Z, et al. Electron and high-dose-rate brachytherapy boost in the conservative treatment of stage I-II breast cancer: first results of the randomized Budapest boost trial. Strahlenther Onkol 2002, 178:615-623.
19. Veronesi U, Orecchia R, Maisonneuve P, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol 2013, 14:1269-1277.
20. Vaidya JS, Wenz F, Bulsara M, et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet 2014, 383:603-613.
21. Van Riet YE, Jansen FH, van Beek M, et al. Localization of non-palpable breast cancer using a radiolabelled titanium seed. Br J Surg 2010, 97:1240-1245.
22. Collette S, Collette L, Budiharto T, et al. Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer a study based on the EORTC trial 22881-10882 'boost versus no boost'. Eur J Cancer 2008, 44:2587-2599.
23. Vrieling C, Collette L, Fourquet A, et al. The influence of patient, tumor and treatment factors on the cosmetic results after Radiotherapy and Breast Cancer Cooperative Groups. Radiother Oncol 2000, 55:219-232.
24. Hau E, Browne LH, Khanna S, et al. Radiotherapy breast boost with reduced whole-breast dose is associated with improved cosmesis: the results of a comprehensive assessment from the St. George and Wollongong randomized breast boost trial. Int J Radiat Oncol Biol Phys 2012, 82:682-689.
25. Mukesh MBI, Barnett GC, Wilkinson JS, et al. Randomized controlled trial of intensity-modulated radiotherapy for early breast cancer: 5-year results confirm superior overall cosmesis. J Clin Oncol 2013, 31:4488-4495.
26. Hau E, Browne L, Capp A, et al. The impact of breast cosmetic and functional outcomes on quality of life: long-term results from the St. George and Wollongong randomized breast boost trial. Breast Cancer Res Treat 2013, 139:115-123.
27. Van Parijs H, Miedema G, Vinh-Hung V, et al. Short course radiotherapy with simultaneous integrated boost for stage I-II breast cancer, early toxicity of a randomized clinical trial. Radiat Oncol 2012, 7:80.
28. Van Werkhoven E, Hart G, Van Tinteren H, et al. Nomogram to predict ipsilateral breast relapse based on pathology review from the EORTC 22881-10882 boost versus no boost trial. Radiother Oncol 2011, 100:101-107.
29. Torres-Roca JF, Eschrich S, Zhao H, et al. Prediction of radiation sensitivity using a gene expression classifier. Cancer Res 2005, 65:7169-7176.
30. Servant N, Bollet MA, Halfwerk H, et al. Search for a gene expression signature of breast cancer local recurrence in young women. Clin Cancer Res 2012, 18:1704-1715.
31. Jones HA, Antonini N, Hart AA, et al. Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. J Clin Oncol 2009, 27:4939-4947.
32. Buchholz TA, Somerfield MR, Griggs JJ, et al. Margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline. J Clin Oncol 2014, 32:1502-1506.
33. Haviland JS, Owen JR, Dewar JA, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 2013, 14:1086-1094.
34. Immink JM, Putter H, Bartelink H, et al. Long-term cosmetic changes after breast-conserving treatment of patients with stage I-II breast cancer and included in the EORTC 'boost versus no boost' trial. Ann Oncol 2012, 23:2591-2598.